New Immunotherapy Therapy Approved for Lymphoma Patients

The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy.

The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is commandeered by cells to avoid detection and attack by the body’s immune system. Since 2015, Keytruda has been approved in patients with advanced bladder cancer, melanoma, head and neck cancer, and lung cancer.

This wave of immunotherapy research, in which Dana-Farber scientists have played a prominent role, focuses on amassing the power of the body’s immune system to seek out and destroy cancer cells.

Margaret Shipp, MD, is also studying the benefits of pembrolizumab (Keytruda) or nivolumab (Opdivo) in patients with non-Hodgkin lymphoma.

“The compelling early data support the clinical evaluation of PD-1 blockade in specific additional lymphoma malignancies,” Shipp says.

Read more from the Leukemia and Lymphoma Society, and learn more about immunotherapy at Dana-Farber.

Make An Appointment

For adults: 877-442-9599

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Patrice Kelly’s Journey from Jimmy Fund Clinic Mom to Breast Cancer Patient: https://t.co/aJbJGCqtb6 https://t.co/53jIyv3pij
Dana-Farber @danafarber
What Is the Difference Between Hodgkin Lymphoma and Non-Hodgkin #Lymphoma? https://t.co/8D8CEtpxDf #infographic https://t.co/v4AuowqTjc
Dana-Farber @danafarber
TOMORROW 6/28: The #DFCImammovan will be at Charles River Community Health - Waltham. Call ☎️ 617.632.1974 or visit… https://t.co/60Ei9tFS1r

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.